The results suggest that aneuploidy plays a key role in aggressive prostate cancer, according to the Amon team, and that the extension of aneuploidy could be used to determine the degree of cancer risk and make therapeutic decisions. In addition to new knowledge about the development and spread of prostate cancer, one day chromosomal data can be “clinically used to inform patients about the stratification and treatment of risk,” says a team led by Angelika Amon of the Massachusetts Institute of Technology. New research suggests that monitoring specific changes in the number of chromosomes in prostate cancer cells can help solve this mystery. Aneuploidy is a well-known brand of cancer, but it is unclear how it affects cancer progression, or whether screening for gains or losses of chromosomes can help control treatment. They then applied this method to 404 patients with prostate cancer who were treated for an average of 15 years. The guide to the treatment of prostate cancer is very necessary, researchers who used samples of prostate cancer from 333 men to develop a method to estimate a “signature” model of gains and losses of chromosomes in those cells. The QUIZ prostate cancer study focuses on a genetic disorder known as aneuploidy, an unusual number of chromosomes in cells.